Nothing Special   »   [go: up one dir, main page]

ECSP16086232A - (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina - Google Patents

(r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Info

Publication number
ECSP16086232A
ECSP16086232A ECIEPI201686232A ECPI201686232A ECSP16086232A EC SP16086232 A ECSP16086232 A EC SP16086232A EC IEPI201686232 A ECIEPI201686232 A EC IEPI201686232A EC PI201686232 A ECPI201686232 A EC PI201686232A EC SP16086232 A ECSP16086232 A EC SP16086232A
Authority
EC
Ecuador
Prior art keywords
pirlindole
pharmaceutically acceptable
acceptable salts
medicine
pain
Prior art date
Application number
ECIEPI201686232A
Other languages
English (en)
Inventor
Pedroso Pedro Filipe Eufrasio
Pecorelli Susana Marques Almeida
Ana Sofia Da Conceicao Lopes
Caixado Carlos Alberto Eufrasio Casimiro
Filipe Augusto Eugenio Pardal
Joao Carlos Ramos Damil
Original Assignee
Tecnimede Sociedade Tecnico Medicinal S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tecnimede Sociedade Tecnico Medicinal S filed Critical Tecnimede Sociedade Tecnico Medicinal S
Publication of ECSP16086232A publication Critical patent/ECSP16086232A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

(R)-pirlindole o sus sales farmacéuticamente aceptables, así como composiciones farmacéuticas que comprenden el mismo para uso en el tratamiento terapéutico y prevención del dolor.
ECIEPI201686232A 2014-05-09 2016-11-09 (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina ECSP16086232A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PT2014/000028 WO2015171004A1 (en) 2014-05-09 2014-05-09 (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine

Publications (1)

Publication Number Publication Date
ECSP16086232A true ECSP16086232A (es) 2017-02-24

Family

ID=50819930

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201686232A ECSP16086232A (es) 2014-05-09 2016-11-09 (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina

Country Status (28)

Country Link
US (2) US20170145015A1 (es)
EP (1) EP3054950B1 (es)
JP (1) JP2017514884A (es)
KR (1) KR102232198B1 (es)
CN (1) CN106413714A (es)
AU (1) AU2014393489B2 (es)
CA (1) CA2948596C (es)
CY (1) CY1119522T1 (es)
DK (1) DK3054950T3 (es)
EC (1) ECSP16086232A (es)
ES (1) ES2649491T3 (es)
HR (1) HRP20171650T1 (es)
HU (1) HUE035030T2 (es)
IL (1) IL248854B (es)
LT (1) LT3054950T (es)
MA (1) MA39448B1 (es)
MX (1) MX368735B (es)
NO (1) NO3054950T3 (es)
NZ (1) NZ726131A (es)
PH (1) PH12016502236A1 (es)
PL (1) PL3054950T3 (es)
PT (1) PT3054950T (es)
RS (1) RS56590B1 (es)
RU (1) RU2695607C2 (es)
SI (1) SI3054950T1 (es)
TN (1) TN2016000497A1 (es)
UA (1) UA116499C2 (es)
WO (1) WO2015171004A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3831385T3 (pl) * 2014-05-09 2024-10-14 Tecnimede Sociedade Tecnico-Medicinal S.A. Sole migdalanowe enancjomerów pirlindolu do stosowania w medycynie
PT3054950T (pt) 2014-05-09 2017-11-29 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindol ou seus sais farmaceuticamente aceitáveis para uso em medicina
KR102421013B1 (ko) 2016-05-19 2022-07-14 에스케이바이오팜 주식회사 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도
US20210386365A1 (en) * 2018-06-13 2021-12-16 Children`S Medical Center Corporation Biomarkers of neuropathic pain

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1558231A4 (en) * 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
BR0317747A (pt) * 2002-12-24 2005-11-22 Neurochem Int Ltd Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
CA2538997A1 (en) * 2003-09-15 2005-03-24 Vectura Limited Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
MX368734B (es) * 2014-05-09 2019-10-14 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
PL3831385T3 (pl) * 2014-05-09 2024-10-14 Tecnimede Sociedade Tecnico-Medicinal S.A. Sole migdalanowe enancjomerów pirlindolu do stosowania w medycynie
PT3054950T (pt) 2014-05-09 2017-11-29 Tecnimede-Sociedade Tecnico-Medicinal S A (r)-pirlindol ou seus sais farmaceuticamente aceitáveis para uso em medicina

Also Published As

Publication number Publication date
RU2016148182A (ru) 2018-06-13
AU2014393489A1 (en) 2016-11-24
RU2695607C2 (ru) 2019-07-24
PT3054950T (pt) 2017-11-29
US20180111944A1 (en) 2018-04-26
PH12016502236A1 (en) 2017-02-06
HUE035030T2 (en) 2018-05-02
LT3054950T (lt) 2017-11-27
AU2014393489B2 (en) 2020-01-02
IL248854A0 (en) 2017-01-31
WO2015171004A1 (en) 2015-11-12
EP3054950A1 (en) 2016-08-17
CY1119522T1 (el) 2018-03-07
PL3054950T3 (pl) 2018-02-28
JP2017514884A (ja) 2017-06-08
CA2948596C (en) 2021-06-08
EP3054950B1 (en) 2017-08-02
NO3054950T3 (es) 2017-12-30
RU2016148182A3 (es) 2018-06-13
UA116499C2 (uk) 2018-03-26
KR20170003567A (ko) 2017-01-09
RS56590B1 (sr) 2018-02-28
US20170145015A1 (en) 2017-05-25
KR102232198B1 (ko) 2021-03-26
SI3054950T1 (sl) 2017-12-29
IL248854B (en) 2020-05-31
CA2948596A1 (en) 2015-11-12
NZ726131A (en) 2018-12-21
HRP20171650T1 (hr) 2017-12-15
TN2016000497A1 (en) 2018-04-04
MX2016014701A (es) 2017-05-23
MA39448A1 (fr) 2018-08-31
MX368735B (es) 2019-10-14
ES2649491T3 (es) 2018-01-12
US10533012B2 (en) 2020-01-14
DK3054950T3 (en) 2017-11-06
MA39448B1 (fr) 2019-12-31
CN106413714A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
NI201600115A (es) Derivados de sulfamoilpirrolamida y su uso como medicamentos para el tratamiento de la hepatitis b.
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CO2017001994A2 (es) Compuestos activos hacia bromodominios
CL2016002027A1 (es) Ciclopropilamina como inhibidor de la lsd1
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
SV2018005687A (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
ECSP17013903A (es) Protein kinase c inhibitors and methods of their use
CL2016003260A1 (es) Profármacos de gemcitabina
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CL2015002897A1 (es) Inhibidores de bace1
CL2017001904A1 (es) Composición para el tratamiento de enfermedad veno-oclusiva hepática.
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
ECSP16086232A (es) (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
IT201600081379A1 (it) Composizione farmaceutica per uso nel trattamento delle patologie prostatiche.
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
EA201700254A1 (ru) Комбинация
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
DOP2016000325A (es) Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas
CL2015003211A1 (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio.
AR099681A1 (es) Composiciones de grapiprant y métodos para su utilización